Poor survival in prostate cancer patients with primary refractoriness to docetaxel

European Urology

Volumn 65, Issue 2, 2014, Pages 505-507

  Di Lorenzo, Giuseppe ^a   Bracarda, Sergio ^b   Buonerba, Carlo ^a   Aieta, Michele ^c   Mirone, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Epilepsy Center   (Italy)

^c UO Oncologia Ospedale Oncologico Regionale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

AGED; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DISEASE DURATION; HUMAN; LETTER; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY PERIOD;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TAXOIDS; TIME FACTORS;

EID: 84891834712     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.10.037     Document Type: Letter

References (11)

1. A. Bahl, S. Masson, A. Birtle, S. Chowdhury, and J. de Bono Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents Cancer Treat Rev 40 2014 170 177
2. C. Buonerba, M. Ferro, and G. Di Lorenzo Sipuleucel-T for prostate cancer: the immunotherapy era has commenced Expert Rev Anticancer Ther 11 2011 25 28
3. G. Di Lorenzo, and C. Buonerba Re: abiraterone in metastatic prostate cancer without previous chemotherapy Eur Urol 63 2013 961
4. C. Buonerba, G.R. Pond, and G. Sonpavde et al. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer Future Oncol 9 2013 889 897
5. A.J. Armstrong, E. Garrett-Mayer, R. de Wit, I. Tannock, and M. Eisenberger Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res 16 2010 203 211
6. G. Di Lorenzo, C. Buonerba, and A. Faiella et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer BJU Int 107 2011 234 239
7. C. Buonerba, G. Palmieri, and G. Di Lorenzo Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice Eur Urol 58 2010 636 637
8. A. Omlin, C. Pezaro, and D. Mukherji et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms Eur Urol 64 2013 300 306
9. D. Mukherji, C.J. Pezaro, and D. Bianchini et al. Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel J Clin Oncol 30 Suppl 2012 abstract 17
10. Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.07. 022
11. G. Di Lorenzo, C. Buonerba, and P.W. Kantoff Immunotherapy for the treatment of prostate cancer Nat Rev Clin Oncol 8 2011 551 611